Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is Ginkgo Bioworks Holdings (DNA) Stock Down -9.68% Today?

Why Is Ginkgo Bioworks Holdings (DNA) Stock Down -9.68% Today?

Key Takeaways

  • DNA shares fell 9.68% to $8.68 in Monday morning trading, extending a sharp two-week retreat from their post-earnings high.
  • No company press release, SEC filing, or fresh fundamental development was identified as the trigger for the session's decline.
  • The pullback is consistent with continued unwinding of the speculative rally that followed third-quarter results on November 5.
  • A bearish analyst backdrop adds weight: consensus sits near "underperform," with an average 12-month target of $8.00, below the current share price.
  • The company has withheld 2027 revenue guidance until February and flagged a six-to-twelve-month lag between autonomous-lab orders and recognized revenue.
  • Trading volume was running well above its normal pace, and the stock traded down to its 200-day moving average near $8.64 before stabilizing.
  • News Significance Score: 19/100 — no verified news, and a decline only about 1.6x the stock's typical daily swing.
  • Investors can dig deeper into Price Targets, Earnings, and Forecast data on Tickeron's dedicated pages.
  • For systematic, rules-based exposure across the market, explore Trending AI Robots.

Opening Summary

Ginkgo Bioworks Holdings, Inc. (DNA) is a Boston-based synthetic biology company that has repositioned itself around autonomous laboratory infrastructure — selling robotic lab systems to pharmaceutical and government customers and renting out capacity at its own Boston facility, Nebula. On Monday, the stock fell 9.68% to $8.68, compared with Friday's close of $9.61. The decline was confirmed in both direction and magnitude, and it extends a slide that has now erased roughly 30% of the share price since the November 9 close. No verified news catalyst was found for the session; the move instead reflects the continued deflation of a post-earnings speculative run in a highly volatile, heavily shorted micro-cap.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found to explain Monday's decline. There was no press release, no 8-K, no financing announcement, and no regulatory development tied to the move. The most defensible assessment is technical: the stock is giving back the last remnants of an earnings-driven spike that briefly doubled the share price between late September and early October, when it ran from about $7.90 to an intraday high of $18.22 on October 6.

Two data points support that read. First, the stock had already fallen in six of the prior seven sessions, sliding from $12.37 on November 9 to $9.61 on November 13, so Monday's drop continued an established downtrend rather than starting a new one. Second, the decline carried the shares to $8.55 intraday, essentially touching the 200-day moving average near $8.64 — a level that has acted as a floor through the autumn rally. A move of this size is also routine for this name: the stock has posted daily swings of 9.7% or more on 18 of the last 69 sessions.

Post-Earnings Unwind and a Bearish Analyst Backdrop

Third-quarter results, released November 5, were genuinely better than expected: revenue of $27.7 million beat consensus of about $21.5 million, the net loss from continuing operations narrowed to $41 million from $73 million, and adjusted EBITDA loss improved 58% year over year. The stock jumped 13% the next session. But the beat leaned on a contract modification that pulled revenue forward, total revenue was still down 6% year over year, and management declined to issue 2027 guidance until February.

That gap gave sell-side analysts little to defend. TD Cowen moved to Hold from Buy with an $11 target, BTIG reiterated a Sell rating and a $5 target, and the broader consensus now sits at underperform with an average target of $8.00 — implying further downside from current levels. Short interest stands at roughly 9.5 million shares, or about 15% of shares outstanding, leaving the name prone to sharp two-way moves as positioning shifts.

Market Context and Trading Activity

Volume was elevated. Roughly 262,000 shares traded in the first fifteen minutes, a pace well above the 20-day average of about 2.5 million shares spread across a full session. The stock opened near $9.31 and sold off in the first half hour rather than gapping lower overnight, which points to active institutional distribution during regular hours rather than an overnight headline.

The move was idiosyncratic. There was no matching catalyst among large-cap biotech peers or lab-automation names, and no confirmed sector-wide event. Ginkgo's beta of 1.74 to 2.6 — depending on the measurement window — means it routinely amplifies broader risk sentiment, and the shares have historically sold off alongside genomics-focused exchange-traded funds during bouts of biotech risk aversion.

News Significance Score

The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 19 out of 100. The verified news component is weak: there was no announcement on Monday, and the most relevant fundamental information — the earnings beat and the subsequent analyst downgrades — is more than a week old and already reflected in the price.

The price component is also modest in context. Monday's 9.68% decline was roughly 1.6 times the stock's average absolute daily move of 6.2% over the past 60 sessions, and moves of similar or larger size occurred 18 times in that window. Two weak components combine into a low score.

What Comes Next for DNA

The next hard catalyst is the fourth-quarter report and, more importantly, 2027 guidance, expected around late February. Management has said it will reset expectations then, including any revenue framework for autonomous-lab hardware and recurring Cloud Lab services. Investors will also watch the cash burn trajectory against full-year guidance of $125 million to $150 million, backed by $285 million in cash and marketable securities with no bank debt.

Commercially, the focus is conversion: the first autonomous-lab sale to Novo Nordisk (NVO), an ARPA-H subcontract worth up to $17.5 million, and cloud-lab customer additions need to translate into revenue. Risks include continued top-line contraction, competition from low-cost contract research organizations, and the possibility that valuation continues to compress toward the analyst consensus target.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the leaders in this list change as market conditions shift. For investors navigating volatile names like this one, it is a practical starting point for comparing live, rules-based strategies side by side.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DNA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


DNA's Stochastic Oscillator is sitting in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +24.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DNA as a result. In 73 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for DNA turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 41 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

DNA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for DNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.809) is normal, around the industry mean (3.592). P/E Ratio (-2.258) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
27 Drydock Avenue
Phone
+1 877 422-5362
Employees
485
Web
https://www.ginkgobioworks.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.